

INFORMATION DISCLOSURE CITATION

Form PTO-1449 (Modified)

(Use several sheets if necessary)

ATTY. DOCKET NO.
IRVN-005CIPSERIAL NO.
09/771,263

APPLICANT

Thompson et al.

FILING DATE
January 26, 2001GROUP
Unassigned

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
CY	AA	4,038,145	07/26/77	Devlin			
	AB	4,677,056	06/30/87	Dupont et al.			
	AC	4,716,111	12/29/87	Osband et al.			
	AD	5,057,423	10/15/91	Hiserodt et al.			
	AE	5,192,537	03/09/93	Osband			
	AF	5,308,626	05/03/94	Landucci et al.			
	AG	5,382,427	01/17/95	Plunkett et al.			
	AH	5,476,993	12/19/95	Richmond			
	AI	5,484,596	01/16/96	Hanna Jr. et al.			
	AJ	5,569,585	10/29/96	Goodwin et al.			
	AK	5,602,305	02/11/97	Pober et al.			
	AL	5,663,481	09/02/97	Gallinger et al.			
	AM	5,837,233	11/17/98	Granger			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
CY	AN	WO 91/01760	02/21/91	PCT				
	AO	WO 95/16775	06/22/95	PCT				
	AP	WO 95/20649	08/03/95	PCT				
	AQ	WO 95/31107	11/23/95	PCT				
	AR	WO 96/05866	02/29/96	PCT				
	AS	WO 96/07433	03/14/96	PCT				


EXAMINER

Chris G L H V

DATE CONSIDERED

5/28/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) <i>Use several sheets if necessary</i>					ATTY. DOCKET NO. IRVN-005CIP		SERIAL NO. 09/771,263	
					APPLICANT Thompson et al.			
					FILING DATE January 26, 2001		GROUP Unassigned	
CY	AT	WO 96/29394	09/26/96	PCT				
	AU	WO 98/04282	02/05/98	PCT				
	AV	WO 98/16238	04/23/98	PCT				
	AW	1,297,002	03/10/92	Canada				
	AX	379 554 B1	05/15/96	Europe				
	AY	0 493 468 B1	04/17/96	Europe				
	AZ	EP 0 645 147	03/29/95	Europe				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CY	BA	Albright et al., (1977) "Immunogenetic control of brain tumor growth in rats" Cancer Research 22:2512-2521.
	BB	Animal Cell Culture: A Practical Approach, R.I. Freshney, ed., (1987) IRL Press, Oxford, Table of Contents, pp. vii-xii.
	BC	Appendix A: Curriculum vitae of Gale A. Granger NO DATE AVAILABLE
	BD	Appendix B (item 1): E.W.B. Jeffes et al. (1993) "Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL2 stimulated killer (MAK) lymphocytes . . ." J. Neuro-Oncol. 15:141-155.
	BE	Appendix B (item 2): R.S. Yamamoto et al. "Basical and clinical studies with intratumor immunotherapy of gliomas with alloimmune lymphoid cells." Poster presentation, American Association of Neurological Surgeons.
	BF	Appendix B (item 3): G. Ioli et al. (1994) "Basic & clinical studies with intratumor immunotherapy of gliomas with allogeneic lymphoid cells" Proc. Amer. Assoc. Cancer Res. 35:518 (Abstract 3088).
	BG	Appendix B (item 4): G. Granger et al. (1995) "Basic and clinical studies of intralesional therapy of gliomas with allogeneic lymphoid cells" Proc. Amer. Assoc. Cancer Res. 36:472 (Abstract 2812).
	BH	Appendix C: Letters regarding Gifts from Good Samaritan Hospital to support research of Gale A. Granger; Table of Gifts
	BI	Appendix D: List of patients treated according to the invention up to September 26, 1996
	BJ	Appendix E: Break-down of charges for alloactivated donor cells produced at U.C.I. NO DATE AVAILABLE
	BK	Appendix F: Curriculum vitae of John C. Hiserodt NO DATE AVAILABLE
	BL	Appendix G: "Immunotherapy for recurrent high grade gliomas: I. A pilot study using intratumoral implants of MLC-activated allogeneic lymphoid cells for the treatment of recurrent malignant astrocytomas" by J.C. Hiserodt, S. Jacques, C. Dumas, and G.A. Granger. [Unpublished manuscript] NO DATE AVAILABLE

EXAMINER Chris L H	DATE CONSIDERED 5/28/02
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. IRVN-005CIP	SERIAL NO. 09/771,263
		APPLICANT Thompson et al.	
		FILING DATE January 26, 2001	GROUP Unassigned
BM	Appendix H: Chart of data from brain cancer patients compiled in 1995		
BN	Appendix I: Data from treated brain cancer patients [compiled for submission to FDA] <i>No DATE AVAILABLE</i>		
BO	Barba et al., (1989) "Intratumoral LAK cell and interleukin-2 therapy of human gliomas" J. Neurosurg. 70:175-182.		
BP	Bellgrau, (1983) "Induction of cytotoxic T Cell precursors in vivo" J. Exp. Med. HZ: 1505-1515.		
BQ	Berd et al. (1990) "Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients." J. Clin. Oncol. Vol. 8, 1858-1867		
BR	Burris et al., (1997) "Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracil." Eur. J. Cancer 33:S18-22		
BS	Burris et al. (1997) "Improvements in survival and clinical benefit with gemdtabine as first-line therapy for patients with advanced pancreas cancer A randomized trial." J. Clin. Oncol. 15:2403-13.		
BT	Carmichael et al., (1996) "Phase 11 study of gemdtabine in patients with advanced pancreatic cancer." Br. J. Cancer 73:101-5		
BU	Carmichael, (1997) "Clinical response benefit in patients with advanced pancreatic cancer. Role of gemcitabine." Digestion 58:503-7		
BV	Carpinito, et al., (1985) "Effective Treatment of Metastatic Carcinoma with In Vitro Immunized Autologous Lymphocytes and Cimetidine," The Journal of Urology, V. 133, No. 4, Part 2, pp. 157A, Abstract 174		
BW	Carpinito, et al., (1996) "Successful Adoptive Immunotherapy of Cancer Using In Vitro Immunized Autolougous Lymphocytes and Cimetidine," Surgical Forum Vol. XXXVII, New Orleans		
BX	Carson et al. (1991) "Rat Mitogen-Stimulated Lymphokine-Activated T Killer Cells: Production and Effects on C6 Glioma Cells In Vitro and In Vivo in the Brain of Wistar Rats", Journal of Immunotherapy, 10: 131 -140		
BY	Casper et al., (1994) "Phase II trial of gemdtabine (2,2'difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas" Invest. New Drugs 12:29-34 (Abstract only)		
BZ	Cavallo et al., (1992) "Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonirnmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene" J. Immunol. 149(11):3627-3635.		
CA	Chang et al., (1997) "Phase I clinical trial of allogeneic mixed lymphocyte culture (cytoimplant) delivered by endoscopic ultrasound (EUS)-guided fine needle injection (FNI) in patients with advanced pancreatic carcinoma" Gastroenterology 112(4): A546.		
CB	Colombo et al., (1995) "Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: do animal studies really support clinical trials?" Cancer Immunol. Immunother. 41:265-270.		
CC	Current Protocols in Immunology, Volume I, J.E. Coligan et al., eds., John Wiley & Sons, Inc., Supplement 28, Table of Contents, pp. 1-9 (1998).		
CD	Current Protocols in Molecular Biology, Volume I, F.M. Ausubel et al., (1995) eds., John Wiley & Sons, Inc., Table of Contents, Supplement 30, 39-40, pp. iii-xii		

EXAMINER <i>Chris Sph HV</i>	DATE CONSIDERED <i>5/28/02</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation not in conformance and not considered. Include copy of this form with next communication to applicant.	

RECEIVED
 APR 04 2001
 TECH CENTER 1600-9900

INFORMATION DISCLOSURE CITATION

Form PTO-1449 (Modified)

(Use several sheets if necessary)

ATTY. DOCKET NO.

IRVN-005CIP

SERIAL NO.

09/771,263

APPLICANT


Thompson et al.

FILING DATE

January 26, 2001

GROUP

Unassigned



CY

CE	Damle et al., (1981) "Autologous Mixed Lymphocyte Reaction in Man. II. Histamine-Induced Suppression of the Autologous Mixed Lymphocyte Reaction by T-Cells Subsets Defined with Monoclonal Antibodies," J. Clin Immunol 1:241-249
CF	Davis et al., (1980) "Antibody Formation Hagerstown," Microbiology 3rd ed., Harper & Row Publishers, Inc., Ch. 19, pp.420-422
CG	DECLARATION BY GALE A. GRANGER regarding Human Clinical Trials NO DATE AVAILABLE
CH	DECLARATION BY JOHN C. HISERODT regarding Human Clinical Trials NO DATE AVAILABLE
CI	Declaration by Tetsuya Gatanaga Pursuant to 37 CFR § 1.56 Regarding Clinical Trial Conducted under IND-6288 (with Appendicies A & B) No Date AVAILABLE
CJ	Dillman et al. (1993) "Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy." J. Immunother. Vol. 14:65-69
CK	Dranoff et al. (1993) "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity." Proc. Natl. Acad. Sci. USA, Vol. 90:3539-3543.
CL	Dugan et al., "Current concepts in pancreatic cancer. Symposium summary." (1998) Pancreas 17:325-33
CM	Eisenthal, A. et al., (1986) "The Effect of Cimetidine on PBL from Healthy Donors and Melanoma Patients: Augmentation of T Cell Responses to TCGF* Mitogens and Alloantigens and of TCGF Production," Cancer Immunol. Immunother. 27:141-147
CN	Finke et al., (1990) "Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma" Cancer Research 50:2363-2370.
CO	Fleshner et al., (1990) "Potential of allogeneic tumoricidal cytotoxic T lymphocytes in brain tumor adoptive immunotherapy" J. Cell. Biochem. Suppl. 0 (14 Part B) page 95 (Abstract CE407).
CP	Fletcher et al. (1987) "Recent Advances in the Understanding of the Biochemistry and Clinical Pharmacology of Interleukin-2", Lymphokine Research, 6:45-57.
CQ	Gastl et al., (1992) "Retroviral Vector-mediated by Lymphokine Gene Transfer Into Human Renal Cancer Cells," Cancer Research 52:6229-6236
CR	Gately (1982) "In vitro studies on the cell-mediated immune response to human brain tumors. I. Requirement for third-party stimulator lymphocytes in the induction of cell-mediated cytotoxic responses to allogeneic cultured gliomas." J. Natl. Cancer. Inst., Vol. 19:1245-1254.
CS	Gifford et al., (1988) "Histamine Type-2 Receptor Antagonist Immune Modulation. I. Increased Cell-Mediated Cytotoxicity in normal and in Down-Regulated Systems," Surgery 103(2):184-192
CT	Giulivi et al., (1986) "Effects of Cimetidine on In Vitro Transformation of Peripheral Monocytes to Macrophages in Healthy Volunteers and Cancer Patients," Intl. J. Immunopharmacol. 5:517-523
CU	Gold et al., (1993) "Adoptive Chemoimmunotherapy for the Treatment of Relapsed and Refractory Solid Tumors Using Ex Vivo Activated Memory T Cells (Autolymphocyte Therapy) and Cyclophosphamide," J. Immunother. 73:213-221
CV	Gold et al., (1993) "Adoptive Chemoimmunotherapy Using Ex Vivo Activated Memory T Cells and Cyclophosphamide: Tumor Lysis Syndrome of a Metastatic Soft Tissue Sarcoma," Am. J. Hematol. 44:42-47

EXAMINER


Christopher H. L.

DATE CONSIDERED

5/28/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
APR 02 2001
TECH CENTER 18002900

 INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. IRVN-005CIP	SERIAL NO. 09/771,263
		APPLICANT Thompson et al.	
		FILING DATE January 26, 2001	GROUP Unassigned
CY	CW	Golumbek et al. (1992) "Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines." J. Immunother., Vol. 12:224-230	
	CX	Gordon et al., (1980) "Cell Mediated Immune Response and Cimetidine," The Michigan Academician pgs. 280-289	
	CY	Graham et al., (1993) "The Use of Ex Vivo- Activated Memory T Cells (Autolymphocyte Therapy) in the Treatment of Metastatic Renal Cell Carcinoma: Final Results From a Randomized, Controlled, Multisite Study," Sem. Urol. 11:27-34	
	CZ	Granger et al., (1995) "Basic and clinical studies of intralesional therapy of gliomas with allogeneic lymphoid cells" Proc. Amer. Assoc. Cancer Res. 36:472 (Abstract 2812).	
	DA	Hayes et al., (1988) "Recombinant interleukin-2-related intracerebral toxicity and LAK/rIL-2 therapy for brain tumors" Lymphokine Res. 2(3):337 (Abstract 9.25).	
	DB	Hidalgo et al., (1999) "Phase III study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer." J. Clin. Oncol. 17:585-92.	
	DC	Jeffes III et al., (1991) "Therapy of recurrent high-grade gliomas with surgery, autologous mitogen-activated IL-2-stimulated (MAK) killer lymphocytes, and rIL-2: II. Correlation of survival with MAK cell tumor necrosis factor production in vitro" Lymphokine and Cytokine Research 10(2):89-94.	
	DD	Kondo et al. (1984) "Rationale for a Novel Immunotherapy of Cancer with Allogeneic Lymphocyte Infusion," Medical Hypotheses 15:241-277	
	DE	Kruse et al. (1990) "Analysis of Interleukin 2 and Various Effector Cell Populations in Adoptive Immunotherapy of 9L Rat Gliosarcoma: ; Allogeneic Cytotoxic T Lymphocytes Prevent Tumor Take," Proc. Natl. Acad. Sci. USA 87:9577-9581	
	DF	Kruse et al. (1996) "Immune Therapy of Recurrent Malignant Gliomas: Intracavitary Allogeneic Cytotoxic T Lymphocytes and Human Recombinant Interleukin-2, " FASEB J. 10(6):A2387	
	DG	Kruse et al., (1997) "Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumour" Biotechnol. Appl. Biochem. 25:1-9.	
	DH	(Galley proof of article that was later published as Biotechnol. Appl. Biochem. (1997) 25(3): 197-205.)	
	DI	Kruse et al., (1997) "Cellular therapy of brain tumors: clinical trials" Advances in Neuro-Oncology II Futura Publishing Company, Chapter 22, pages 487-504.	
	DJ	Kruse et al., (1994) "Migration of activated lymphocytes when adoptively transferred into cannulated rat brain" J. Neuroimmunol. 55:11-21.	
	DK	Kruse et al., (1993) "Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma" J. Neuro-Oncology 15:97-112.	
	DL	Kruse et al., (1994) "Intracranial Administration of Single of Multiple Source Allogeneic Cytotoxic T Lymphocytes: Chronic Therapy for Primary Brain Tumors," J. Neurooncol. 19:161-168	
	DM	Kruse et al., (1995) "Development of Human Allogeneic CTL in an Artificial Capillary System for Intracavitary Treatment of Malignant Glioma, " Proc. Am. Assoc. Cancer Res. 36:474	
	DN	Lavin et al., (1992) "Autolymphocyte Therapy for Metastatic Renal Cell Carcinoma: Initial Clinical Results From 335 Patients Treated in a Multisite Clinical Practice," Transplant Proc. 24:3059-3064.	

EXAMINER Chen Yuh H Y ~	DATE CONSIDERED 5/28/02
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

RECEIVED
 APR 04 2001
 TECH CENTER 1600/2000

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) <i>Use several sheets if necessary</i>		ATTY. DOCKET NO. IRVN-005CIP	SERIAL NO. 09/771,263
		APPLICANT Thompson et al.	
		FILING DATE January 26, 2001	GROUP Unassigned
CY ↓	DO	Leshem et al., (1984) "In vitro elicitation of cytotoxic response against a nonimmunogenic murine tumor by allosensitization," <u>Cancer Immunology Immunotherapy</u> 17:117-123	
	DP	Lillehei et al. (1991) "Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy." <u>Neurosurgery</u> , Vol. 28:16-23.	
	DQ	Ioli et al., (1994) "Basic & clinical studies with intratumor immunotherapy of gliomas with allogeneic lymphoid cells" <u>Proc. Amer. Assoc. Cancer Res.</u> 35:518 (Abstract 3088).	
	DR	Marshall et al., (1989) "Effects of Coumarin (1,2-Benzopyrone) on Lymphocyte, Natural Killer Cell, and Monocyte Functions In Vitro," <u>J. Biol. Resp. Modifiers</u> 8: 70-85	
	DS	McCarty, M.F., (1985) "Addendum: Cimetidine as an Adjuvant for Allogeneic Lymphocyte Immunotherapy of Cancer" <u>Medical Hypotheses</u> 77:155-156	
	DT	Merchant et al. , (1988) "Adoptive Immunotherapy for Recurrent Glioblastoma Multiforme Using Lymphokine Activated Killer Cells and Recombinant Interleukin-2," <u>Cancer</u> 62:665-671	
	DU	Merchant et al., (1990) "Immunotherapy for Malignant Glioma Using Human Recombinant Interleukin-2 and Activated Autologous Lymphocytes . A Review of Pre-clinical and Clinical Investigations," <u>J. Neurooncol</u> . 8:173-188	
	DV	Methods in Enzymology, Volume LVIII, Cell Culture, W.B. Jakoby et al., eds., (1979) Academic Press, New York, Table of Contents, pp. v-viii	
	DW	Michael et al., (1997) "Clinical experience with gemcitabine in pancreatic carcinoma." <u>Oncology</u> 11:1615-25	
	DX	Miller, J.M. & Calos, M.P. eds., (1987) "Gene Transfer Vectors for Mammalian Cells" Table of Contents, pp. vii-ix	
	DY	Mitchell et al., (1993) "Active specific immunotherapy of melanoma with allogeneic cell lysates" <u>Ann. N.Y. Acad. Sci.</u> 690:153-166.	
	DZ	Molecular Cloning: A Laboratory Manual, Second Edition, J. Sambrook et al., eds., (1989) Cold Spring Harbor Laboratory Press, Table of Contents, pp. xi-xxxviii	
	EA	Naganuma et al., (1989) "Complete remission of recurrent glioblastoma multiforme following local infusions of lymphokine activated killer cells" <u>Acta. Neurochir.</u> 99:157-160.	
	EB	<u>Oligonucleotide Synthesis: A Practical Approach</u> , M.J. Gait, ed., (1984) IRL Press, Oxford, Table of Contents, pp. vii-xii	
	EC	Osband et al., (1990) "Effect of Autolymphocyte Therapy on Survival and Quality of Life in Patients with Metastatic Renal-Cell Carcinoma," <u>Lancet</u> 335:994-998	
	ED	Osband et al., (1981) "Successful Tumour Immunotherapy with Cimetidine in Mice," <u>Lancet</u> 1:636-638	
	EE	Osband, et al., (1986) "Improved Adoptive Cell Immunotherapy by Pre-Infusion Depletion of Suppressor Cells and In Vivo Suppressor Cell Blockade," <u>Proceedings of ASCO</u> , Vol. 5, pp. 232, Abstract 908	
	EF	Palacios, et al., (1980) "Cimetidine Abrogates Suppressor T Cell Function In Vitro," <u>Immunology Letters</u> , Vol. 3:33-37	
EG	Pardoll, (1992) "New Strategies for Active Immunotherapy with Genetically Engineered Tumor Cells," <u>Current Opinion in Immunology</u> 4:619-623		
EH	Penhaligon, et al. (1984) "Antimetastatic Effect of Cimetidine on Mice Bearing a C3H Mouse Mammary Adenocarcinoma: Survival and Lymphocyte Function Studies," <u>Clin. Exp. Metastasis</u> , Vol. 2, No. 1:37-5		

EXAMINER

Christopher H Yea

DATE CONSIDERED

5/28/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
APR 04 2001
TECH CENTER 1000/2000

INFORMATION DISCLOSURE CITATION

Form PTO-1449 (Modified)

(Use several sheets if necessary)

ATTY. DOCKET NO.
IRVN-005CIPSERIAL NO.
09/771,263

APPLICANT

Thompson et al.

FILING DATE

January 26, 2001

GROUP

Unassigned



27	EI	Plaut et al., (1975) "Properties of a Subpopulation of T Cells Bearing Histamine Receptors," J. Clin. Invest. 55:856-874
	EJ	Protocol 1 (item 1): Phase I trial for brain cancer, Good Samaritan Hospital. Protocol version originally filed with the IRB at the Good Samaritan Hospital.
	EK	Protocol 1 (item 2): Phase I trial for brain cancer, Good Samaritan Hospital. Protocol version as subsequently amended to cover 20 patients.
	EL	Protocol 1 (item 3): "Informed Consent Form" (Patient) <i>NO DATE</i>
	EM	Protocol 2 (item 1): Phase I trial for brain cancer, Long Beach Memorial Hospital <i>NO DATE</i>
	EN	Protocol 2 (item 2): "Consent to Act as a Research Subject" (Donor) <i>NO DATE</i>
	EO	Protocol 2 (item 3): "Consent to Act as a Research Subject" (Patient) <i>NO DATE</i>
	EP	Protocol 3 (item 1): Phase I trial for metastatic melanoma, U.C.I. Medical Center <i>NO DATE</i>
	EQ	Protocol 3 (item 2): "Consent to Act as a Human Research Subject" (Donor) <i>NO DATE</i>
	ER	Protocol 3 (item 3): "Consent to Act as a Human Research Subject" (Patient) <i>NO DATE</i>
	ES	Protocol 4 (item 1): Phase I trial for pancreatic cancer, U.C.I. Medical Center <i>NO DATE</i>
	ET	Protocol 4 (item 2): "Consent to Act as a Human Research Subject" (Patient) <i>NO DATE</i>
	EU	Protocol 4 (item 3): "Consent to Act as a Human Research Subject" (Donor) <i>NO DATE</i>
	EV	Protocol 5 (item 1): Phase I trial for bladder & prostate cancer, U.C.I. Medical Center <i>NO DATE</i>
	EW	Protocol 5 (item 2): "Consent to Act as a Human Research Subject" (Patient) <i>NO DATE</i>
	EX	Protocol 5 (item 3): "Consent to Act as a Human Research Subject" (Donor) <i>NO DATE</i>
	EY	Protocol 6: Phase II trial for brain cancer, Good Samaritan Hospital <i>NO DATE</i>
	EZ	Protocol 7: Phase II trial for brain cancer, U.C.I. Medical Center <i>NO DATE</i>
	FA	Protocol for Phase I study at Hospital of the Good Samaritan, "A Phase I study to establish the effects of intratumor implants of allogeneic peripheral blood mononuclear cells (PBM), sensitized against patient alloantigens by MLC, in patients with recurrent glioblastoma" Principal Investigators: Deane Jacques, M.D. and Gale A. Granger, Ph.D. <i>NO DATE</i>
	FB	Redd et al., (1992) "Allogeneic Tumor-specific Cytotoxic T Lymphocytes," Cancer Immunol. Immunother. 34:349-354
	FC	Remington's Pharmaceutical Sciences, 18 th Edition, A.R. Gennaro, ed., (1990) Mack Publishing Co., Easton, PA, Table of Contents, pp. xv-xvi
	FD	Richtsmeier et al., (1987) "Selective, Histamine-Mediated Immunosuppression in Laryngeal Cancer," Ann. Otol. Rhinol. Laryngol. 96:569-572
	FE	Rosenberg et al., (1990) "Gene Transfer into Humans - Immunotherapy of Patients with Advanced Melanoma, Using Tumor-infiltrating Lymphocytes Modified by Retroviral Gene Transduction," New England Journal of Medicine 323:570-578

EXAMINER

Christopher HX

DATE CONSIDERED

5/28/02


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
APR 02 2001
PATENT CENTER 1600/2000

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) (Use several sheets if necessary)		ATTY. DOCKET NO. IRVN-005CIP	SERIAL NO. 09/771,263
		APPLICANT Thompson et al.	
		FILING DATE January 26, 2001	GROUP Unassigned
CY ↓	FF	Rosenberg et al. , (1987) "A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-activated Killer Cells and Interleukin-2 or high-dose interleukin-2 alone," New England Journal of Medicine 316:889-897	
	FG	Rotherberg et al., (1996) "A phase 11 trial of gemcitabine in patients with 5-FU-refractory pancreas cancer." Ann. Oncol. 7:347-53	
	FH	Saito et al. , (1994) "Immunotherapy of Bladder Cancer with Cytokine Gene-Modified Tumor Vaccines," Cancer Research 54:3516-3520	
	FI	Santin et al. (1995) "Development and characterization of an IL-4 secreting human ovarian carcinoma cell line." Gynecol. Oncol., Vol. 58:230-239.	
	FJ	Santin et al. (1996) "Development and characterization of an interleukin-2-transduced human ovarian tumor vaccine not expressing major histocompatibility complex molecules." Am. J. Obst. Gynecol., Vol. 174: 633-639.	
	FK	Santin et al. (1995) "Development and in vitro characterization of a GM-CSF secreting human ovarian carcinoma tumor vaccine." Int. J. Gynecol. Cancer, Vol. 5:401-410.	
	FL	Schiltz et al., (1995) "Movement of allogeneic cytotoxic T lymphocytes (aCTL) infused into the parietal region of 9L gliosarcoma bearing brain" Proceedings of the American Association for Cancer Research 36:458 (Abstract 272)	
	FM	Schiltz et al., (1995) "Treatment of 9L gliosarcoma with interferon-gamma enhances its cytotoxicity by alloreactive cytotoxic T lymphocytes in vitro" FASEB J. 9(4):A1044 (Abstract 6052).	
	FN	Schirmacher et al. , (1995) "Workshop: Active Specific Immunotherapy with Tumor Cell Vaccines," J. Cancer Res. Clin. Oncol. 121:487-489	
	FO	Stephens, (1998) "Gemcitabine: A new approach to treating pancreatic cancer." Oncol. Nurs. Forum 25:87-93	
	FP	Stomiolo et al., (1999) "An investigational new drug treatment program for patients with gemcitabine." Cancer 15: 1261-8.	
	FQ	Strausser et al. , (1981) "Lysis of Human Solid Tumors by Autologous Cells Sensitized In Vitro to Alloantigens," J. Immunol. 127:266-271	
	FR	Streilein, (1995) "Unraveling Immune Privilege" Science 270:1158-1159.	
	FS	The Polymerase Chain Reaction, K.B. Mullis et al., eds., (1994) Birkhauser, Boston, MA, Table of Contents, pp. xv-xvii	
	FT	Topalian et al., (1988) "Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: A pilot study" J. Clinical Oncology 6(5):839-853.	
	FU	Vieweg et al. , (1994) "Immunotherapy of Prostate Cancer in the Dunning Rat Model: Use of Cytokine Gene Modified Tumor Vaccines," Cancer, Res. 54:1760-1765	
	FV	Weir's Handbook of Experimental Immunology, Fifth Edition, Volume I, Immunochimistry and Molecular Immunology, D.M. Weir et al., eds., (1996) Blackwell Science, Cambridge, MA, Table of Contents, pp. v-xii	
FW	Yoshida et al., (1988) "Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors" Cancer Research 48:5011-5016.		

EXAMINER Christopher H. X.	DATE CONSIDERED 5/28/01
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

RECEIVED
APR 4 2001
TECH CENTER 1600/2900



PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project (PTO/SB/08a), no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete If Known			
		Application Number	09/771,263		
		Filing Date	January 26, 2001		
		First Named Inventor	GRANGER, GALE A.		
		Art Unit	1643		
		Examiner Name	YAEN, CHRISTOPHER H.		
Sheet	1	of	1	Attorney Docket Number	IRVN-005CIP

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
ICYI		US- 5,126,132		06/30/1992	Rosenberg	
ICYI		US- 6,121,044		09/19/2000	Peshwa, et al.	
		US-				
		US-				

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² -Number ⁴ -Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/CY/		A. Adler et al. Allogeneic human liposomal melanoma vaccine with or without IL-2 I metastatic melanoma patients: clinical and immunogiological effects. Cancer Biother. 10:293-306, 1995.		
/CY/		G.T. Elliott et al. Interim results of a phase II multicenter clinical trial evaluating the acitivity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin. Surg. Oncol. 9:264-72, 1993.		
/CY/		J.I. Mayordomo et al. Bone marrow derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1:1297-302, 1995.		
/CY/		R.E. Toes et al. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res. 56:3782-7, 1996		

Examiner Signature	/Christopher Yaen/ (04/30/2007)	Date Considered	04/30/2007
-----------------------	---------------------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.